Search

The article discusses the study conducted on the rat's brain to search for new oximes with higher reactivation potency and a broader spectrum, K-27 and K-48, in the U.S. To test their effectiveness in relation to better penetration across the blood-brain barrier, the brain entry was compared with that of obidoxime when it is administered either alone or after the organophosphate paraoxon (POX). During the experiment, rats received doses of obidoxime, K-27 or K-48, either alone or after the organophosphate paraoxon. Result shows that the entry of all three oximes in the brain are minimal and cannot explain the better therapeutic efficacy of K-27 and K-48.